Markus Warmuth
Directeur Général chez MONTE ROSA THERAPEUTICS, INC.
Fortune : 2 M $ au 30/04/2024
Profil
Dr. Markus Warmuth, MD, is a President, Chief Executive Officer & Director at Monte Rosa Therapeutics, Inc., a Venture Partner at Versant Venture Management LLC, an Independent Director at IMV, Inc. and a Chief Executive Officer at Monte Rosa Therapeutics AG.
He is on the Board of Directors at Ventus Therapeutics U.S., Inc., Ventus Therapeutics, Inc., Monte Rosa Therapeutics, Inc. and IMV, Inc. Dr. Warmuth was previously employed as a President & Chief Executive Officer by H3 Biomedicine, Inc., a Head-Oncology Pharmacology by Novartis Institute for Functional Genomics, Inc., and a Director-Kinase Biology by Novartis Institutes for Biomedical Research, Inc. He also served on the board at Relay Therapeutics, Inc. He received his doctorate degree from Ludwig-Maximilians-Universität München.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2024 | 416 538 ( 0,83% ) | 2 M $ | 30/04/2024 | |
IMV INC.
-.--% | 31/03/2023 | 0 ( -.--% ) | - $ | 31/12/2023 |
Postes actifs de Markus Warmuth
| Sociétés | Poste | Début |
|---|---|---|
| IMV INC. | Directeur/Membre du Conseil | 06/11/2018 |
| MONTE ROSA THERAPEUTICS, INC. | Directeur Général | 01/01/2020 |
Monte Rosa Therapeutics AG
 Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Directeur Général | - |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Investor | 01/01/2020 |
Ventus Therapeutics, Inc.
 Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada. | Directeur/Membre du Conseil | 07/12/2021 |
Ventus Therapeutics U.S., Inc.
 Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA. | Directeur/Membre du Conseil | 07/12/2021 |
Anciens postes connus de Markus Warmuth
| Sociétés | Poste | Fin |
|---|---|---|
| RELAY THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/08/2019 |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Directeur Général | 01/05/2018 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Markus Warmuth
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| RELAY THERAPEUTICS, INC. | Health Technology |
| IMV INC. | Health Technology |
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Monte Rosa Therapeutics AG
Monte Rosa Therapeutics AG Pharmaceuticals: MajorHealth Technology Monte Rosa Therapeutics AG develops, manufactures and distributes cancer drugs that modulate protein degradation pathways. The company was founded in 2018 and is headquartered in Basel, Switzerland. | Health Technology |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Ventus Therapeutics, Inc.
Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada. | Health Technology |
Ventus Therapeutics U.S., Inc.
Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA. | Distribution Services |